Product Center
Ab&B Bio-Tech Co., Ltd. Shines on the 2025 European International Pharmaceutical Stage
- Categories:Company news
- Author:
- Origin:
- Time of issue:2025-11-06
- Views:
(Summary description)From October 13th to 16th, the overseas business team of Ab&B Bio-Tech Co., Ltd. made a wonderful appearance at the World Vaccine Congress 2025 Europe held in Amsterdam, Netherlands.
Ab&B Bio-Tech Co., Ltd. Shines on the 2025 European International Pharmaceutical Stage
(Summary description)From October 13th to 16th, the overseas business team of Ab&B Bio-Tech Co., Ltd. made a wonderful appearance at the World Vaccine Congress 2025 Europe held in Amsterdam, Netherlands.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2025-11-06 08:57
- Views:
From October 13th to 16th, the overseas business team of Ab&B Bio-Tech Co., Ltd. made a wonderful appearance at the World Vaccine Congress 2025 Europe held in Amsterdam, Netherlands. As the top vaccine professional event in Europe, this exhibition brings together 2500+industry elites, 280+authoritative spokespersons, and 150+participating companies from around the world, covering the entire value chain of vaccine research and development, production, and supply chain, focusing on core issues such as emerging disease vaccines.
During the exhibition, the company focused on showcasing cutting-edge innovative products such as mRNA monkeypox vaccine and quadrivalent influenza virus subunit vaccine. With diversified innovative research pipelines and mature industrialization capabilities, it attracted widespread attention from many attendees.
The team has received over 20 global clients and partners, completed more than 3 one-on-one in-depth negotiations, and successfully reached a preliminary cooperation intention covering technology licensing, joint research and development, and overseas market expansion. By actively participating in industry forums, the team has synchronized European vaccine regulatory policies with cutting-edge technological innovation trends, laying a solid foundation for the overseas business development of innovative products in the future.
Following closely behind, from October 28th to 30th, Ab&B Bio-Tech Co., Ltd. once again participated in the CPHI 2025 Europe held in Frankfurt, Germany. This top-level event in the global pharmaceutical industry has attracted over 3000 companies from more than 120 countries and regions to participate.
In this exhibition, the company focused on promoting overseas markets, with a particular emphasis on core products such as subunit influenza vaccines and multi-level cooperative businesses. During the exhibition, the team accurately connected with customers from emerging markets such as Morocco, Pakistan, and Mexico, and conducted in-depth negotiations on topics such as product procurement, regional agency, and technical cooperation, fully demonstrating the product competitiveness and cooperation sincerity of Ab&B Bio-Tech Co., Ltd..
The successful participation in two international exhibitions is not only a concentrated display of Ab&B Bio-Tech Co., Ltd.'s technological strength and brand image, but also a crucial step for our overseas expansion.
At present, the company has established a graded follow-up list of potential customers based on valuable clues obtained from the exhibition, ensuring that all cooperation details are carried out in an orderly manner.
 |
 |
In the future, Ab&B Bio-Tech Co., Ltd. will fully utilize the market insights gained from this event, optimize product and service solutions in a targeted manner, develop precise research pipelines, and steadily promote the globalization of the enterprise
Relevant information
-
Ab&B Bio-Tech Co., Ltd. collaborates with Walvax Biotechnology Co., Ltd. to seamlessly connect the third-generation subunit influenza vaccine and embark on a new journey of going globalOn March 13, 2026, Ab&B Bio-Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") and Walvax Biotechnology Co., Ltd. (hereinafter referred to as "Walvax") officially signed a strategic cooperation agreement for the overseas market of influenza virus subunit vaccines in Taizhou. Both parties announced that they will jointly promote the development of the influenza virus subunit vaccine independently developed by Ab&B Bio and set sail to the sea. This is not only a milestone moment for Chinese vaccine companies to cooperate and build a healthy industry ecosystem, but also signifies that China will bring safer and more effective solutions to the global influenza prevention and control field. - Monkeypox mRNA Vaccine Secures FDA Clinical Approval, Trivalent Influenza Virus Subunit Vaccine Wins First Bid in Shanxi 03-04
- Announcement of Pre increase in Performance for 2025 Released 02-26
- Ab&B Bio-Tech Co., Ltd. has been included in the Hang Seng Composite Index, and its recognition in the capital market continues to increase 02-16
- The study on pregnant women receiving quadrivalent influenza virus subunit vaccine has successfully completed key enrollment 02-10
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
